Conor Killmurray | Contributors

Keytruda and Chemotherapy Combination Broadens Number of Treatable Patients with TNBC

January 08, 2021

In an interview with CURE®, lead study investigator of the Keynote 355 trial, Dr. Hope S Rugo, discusses the results of the study that led to the FDA approval of the combination therapy and what further data means for certain patients with metastatic triple-negative breast cancer.

Friday Frontline: Leukemia Survivor Organizes Essential Blood Drives During Pandemic, A Kindergarten Teacher Teaches Her Students During Chemo Sessions Through Zoom, And More

January 08, 2021

From one leukemia survivor organizing essential blood drives for patients with cancer as COVID-19 delays hit, to a kindergarten teacher handling a recurrence of ovarian cancer by continuing to teach her students through Zoom, here’s what’s happening in the cancer landscape this week.

Friday Frontline: Ohio Law Eliminates ‘Fail First’ Insurance Provision for Patients with Stage 4 Cancer, COVID-19 Becomes the Third Leading Cause of Death Behind Cancer And More

December 25, 2020

From the Ohio state legislature tackling the “fail first” provision insurances put in place to keep patients with advanced cancer on generic drugs that are less effective to COVID-19 becoming the third leading cause of death in the United States behind cancer, here’s what happened in the cancer landscape this week.